A Clinical Trial Study of Knee System in Primary Total Knee Arthroplasty in China
A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Knee Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China
- The First Affiliated Hospital of Anhui Medical University
-
-
Beijing
-
Beijing, Beijing, China
- Peking Union Medical College Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China
- General Hospital of Guangzhou Military Command of PLA
-
-
Hunan
-
Changsha, Hunan, China
- Xiangya Hospital Central South University
-
-
Ningxia
-
Yinchuan, Ningxia, China
- The affiliated hosoital of Ningxia Medical University
-
-
Shandong
-
Qingdao, Shandong, China
- The Affiliated Hospital of Qingdao University
-
-
Shanxi
-
Xi'an, Shanxi, China
- Xijing Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China
- The West China Hospital of Sichuan University
-
-
Xinjiang
-
Urumqi, Xinjiang, China
- The First Teaching Hospital of Xinjiang Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- . The subject is ≥18years old
- . The Subject must be of Chinese ethnic descent and be willing to return on three occasions for clinical evaluations.
- . Subject is a suitable candidate for cemented primary TKA using the devices described in this CIP with either resurfaced or non-resurfaced patellae.
- . Subject must meet all criteria specified in BOTH China Knee stem and P.F.C.® Sigma knee instructions for use (IFU)
- . Before surgery, subject is willing and able to sign the informed consent form approved by the Institutional Review Board (IRB), Ethics Committee (EC) or Ethical Review Board (ERB).
- . Subject, in the opinion of the Clinical Investigator, is able to understand this clinical investigation and co-operate with investigational procedures.
- . Subject must be comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the patient reported outcomes (PROs) in the CIP.
- . Subject is receiving a unilateral knee replacement or, if a contralateral knee replacement is anticipated, the surgery must occur within 6 months of the first study knee TKA. The second knee will not be enrolled in the study.
Exclusion Criteria:
- Subject does not provide written voluntary consent to participate in the clinical study.
- The Subject is a woman who is pregnant or lactating.
- Subject is anticipated to require a contralateral TKA between 6 months and 1 year.
- Contralateral knee has already been enrolled in this study.
- Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.
- Subject has a malignant disease, severe condition, alcohol or drug addiction and/or mental disorders that the investigator believes will interfere with the study participation.
- Subjects with severe osteoporosis, metabolic bone disease, radioactive bone disease or tumor in bone surrounding knee joint that, in the opinion of the investigator, will negatively impact implant fixation and the outcome of the investigation
- Subject has significant neurological or musculoskeletal disorders or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, cerebral infarction, hemiplegia, Charcot disease).
- Subject is not comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the PROs in the CIP.
- Subject has a medical condition with less than 2 years of life expectancy.
- The Subject has comorbid condition(s) that could limit the Subject's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.
- The Subject is currently participating in another investigational drug or device study.
- Subject is a prisoner.
- The Subject has a known allergy to any implant components (metal for example).
- Hemoglobin < 11 g/dL
- Albumin < 90% normal low limit
- CRP > 2 times normal upper limit
- ESR > 2 times normal upper limit
Subjects who have abnormal coagulation exam results and cannot be corrected by drugs or plasma replacement
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Total Knee System made in China
Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
|
SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
|
|
Active Comparator: Total Knee System made outside of China
Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
|
SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
12-month post-op AKS
Time Frame: 12 months postoperatively
|
12 months postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Non-revision rates(revision for any reason) through the end of the study
Time Frame: 12 months postoperatively
|
12 months postoperatively
|
|
One year non-revision rate where revision is defined as removal of any component secondary to infection
Time Frame: 12 months postoperatively
|
12 months postoperatively
|
|
American Knee Society Total Score success (where success is defined as a score of 80 points or higher)at the 1 year follow-up inerval
Time Frame: 12 months postoperatively
|
12 months postoperatively
|
|
Short-form 12(SF-12) general health questionnaire each of 8 dimensions and the overall Physical and Mental health domains, at 1-year follow-up interval.
Time Frame: Preoperation to12 months postoperatively
|
Preoperation to12 months postoperatively
|
|
WOMAC scores at the 1-year follow-up interval
Time Frame: Preoperation to12 months postoperatively
|
Preoperation to12 months postoperatively
|
|
Radiogrphic assessment of clinically relevant radiolucent line(RLL)and osteolysis,migration and subsidence, by comparing the 3 month post-operative x-ray to the 1 year follow up x-ray inerval.
Time Frame: Preoperation to12 months postoperatively
|
Preoperation to12 months postoperatively
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The proportion of Composite Successes in each treatment group will be assessed at the 1year follow-up interval
Time Frame: 12 months postoperatively
|
12 months postoperatively
|
|
Blood samplets will be collected and data will be summarized
Time Frame: pre-operative and immediate post-operatively
|
pre-operative and immediate post-operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Fuxing Pei, The West China Hospital of Sichuan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DPS-201302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.